Direct renin inhibitors: The dawn of a new era, or just a variation on a theme?

Nephrology Dialysis Transplantation

Volumn 22, Issue 9, 2007, Pages 2435-2439

  Segall, Liviu ^a   Covic, Adrian ^a   Goldsmith, David J A ^b  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Chronic kidney disease; Direct renin inhibitors; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR BLOCKING AGENT; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROCHLOROTHIAZIDE; IRBESARTAN; PLACEBO; RAMIPRIL; RECEPTOR BLOCKING AGENT; REMIKIREN; RENIN; RENIN INHIBITOR; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; MONOTHERAPY; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

DRUG THERAPY, COMBINATION; HUMANS; KIDNEY FAILURE, CHRONIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 34548410541     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm363     Document Type: Review

References (39)

1. Rüster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991
2. Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: Renoprotective effects of aldosterone blockade. J Pharmacol Sci 2006; 100: 9-16
3. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 2005; 366: 2026-2033
4. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49: 12-26
5. Hollenberg NK, Fisher NDL. Renal circulation and blockade of the renin-angiotensin system. Hypertension 1995; 26: 602-609
6. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67: 799-812
7. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer J-D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 10: 1417-1427
8. Hamming I, Navis G, Kocks MJ, van Goor H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J Pathol 2006; 209: 129-139
9. Naruse M, Tanabe A, Sato A et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33
10. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type I receptor antagonists. Circulation 2004; 109: 2492-2499
11. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients, with chronic, heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet. 2003; 362: 767-771
12. Ruilope LM, Aldigier JC, Ponticelli C et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease: European, Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000; 18: 89-95
13. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant 2006; 21: 854-858
14. Bianchi S, Bigazzi R, Campese VM. Long-terra effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 21116-2123
15. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553
16. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension 2002; 39: El-e8
17. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993; 43: 1-20
18. Fisher NDL, Hollenberg NK. Renin inhibition: What are the therapeutic opportunities? J Am Soc Nephrol 2005; 16: 592-599
19. O'Brien E, Barton J, Nussberger J et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276-284
20. Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: Is oral renin inhibition the solution? Expert Opin Pharmacother 2007; 8: 529-535
21. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449-1456
22. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 2006; 70: 1905-1913
23. Tekturna (aliskiren). Prescribing information (http://www.fda.gov)
24. Mitchell J, Oh B, Herron J et al. Once-daily aliskiren provides effective, smooth 24-hour blood pressure control in patients with hypertension. J Clin Hypertens 2006; 8 [5 Suppl. A]:A93(P-209). Poster presented at ASH 2006
25. Feldman DL, Persohn E, Schutz H et al. Renal localization of the renin inhibitor aliskiren. J Clin Hypertens 2006; 8 [Suppl. A]: A80
26. Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent anti-hypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018
27. Villamil A, Chrysant S, Calhoun D et al. The novel oral renin inhibitor aliskiren provides effective blood pressure control in patients with hypertension when used alone or in combination with hydrochlorothiazide. J Clin Hypertens 2006; 8 [Suppl. A]: A101
28. Uresin Y, Taylor A, Kilo C et al. Aliskiren, a novel rennin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Hypertens 2006; 24 [Suppl. 4]: S82
29. Munger MA, Drummond W, Essop MR et al. Aliskiren as addon to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Abstract presented at WCC/ESC, Barcelona, Spain, 2-6 September, 2006 (P784)
30. Pool JL, Schmieder RE, Azizi M et al. Aliskiren, an orally effective rennin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11-20
31. Clozel JP, Veniant MM, Qiu C, Sprecher U, Wolfgang R, Fischli W. Renal vascular and biochemical responses to systemic rennin inhibition in dogs at low renal perfusion pressure. J Cardiovasc Pharmacol 1999; 34: 674-682
32. Verburg KM, Kleinert HD, Chekal MA, Kadam JRC, Young GA. Renal hemodynamic and excretory responses to renin inhibition induced by A-64662. J Pharmacol Exp Ther 1990; 252: 449-455
33. El Amrani AIK, Ménard J, Gonzales MF, Michel JB. Effects of blocking the angiotensin II receptor, converting enzyme, and rennin activity on the renal hemodynamics of normotensive Guinea pigs. J Cardiovasc Pharmacol 1993; 22: 231-239
34. Fisher NDL, Allan D, Kifor I et al. Responses to converting enzyme and renin inhibition: Role of angiotensin II in humans. Hypertension 1994; 23: 44-51
35. van Paassen P, de Zeeuw D, Navis G, de Jong PE. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant 2000; 15: 637-643
36. Pilz B, Shagdarsuren E, Wellner M et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46: 569-576
37. Feldman D, Jin L, Miserindinomoltini R, Xuan H, Luft F, Muller D. Aliskiren, a human renin inhibitor induces persistent renoprotection comparable to ACE inhibition in double transgenic rats (dTGR). Am J Hypertens 2005; 18: A230
38. Shagdarsuren E, Wellner M, Braesen JH et al. Complement activation in angiotensin II-induced organ damage. Circ Res 2005; 97: 716-724
39. Chris Jensen J. SPP100 (Aliskiren). The journey from the laboratory bench to market. www.speedel.com